[PharmaEssentia] Announcement on the Completion of Registration for Capital Reduction via Cancellation of Restricted Employee Shares
PharmaEssentia announced that it completed the capital reduction registration for the cancellation of restricted employee shares on May 25, 115. Paid-in capital is now 3,799,013,700 NTD, and the book value per share remains at 92.71 NTD.
📋 Article Processing Timeline
- 📰 Published: May 25, 2026 at 09:00
- 🔍 Collected: May 26, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 26, 2026 at 09:23 (1h 23m after Collected)
1. Date approved by competent authority for capital reduction: May 25, 115
2. Date of completion of capital change registration: May 25, 115
3. Impact on financial statements (including differences in paid-in capital, shares outstanding, and book value per share):
Before Reduction: Paid-in Capital 3,799,093,700 NTD, Outstanding Shares 371,637,704, Book Value per Share 92.71 NTD
After Reduction: Paid-in Capital 3,799,013,700 NTD, Outstanding Shares 371,629,704, Book Value per Share 92.71 NTD
Note: Book value per share is calculated based on the financial statements reviewed by accountants for Q1 of 115.
4. Planned share exchange schedule: N/A
5. Expected listed common shares after reduction: N/A
6. Ratio of expected listed common shares to total issued common shares after reduction: N/A
7. Countermeasures for low liquidity: N/A
8. Other important items: The number of restricted employee shares canceled in this instance is 8,000 shares.
2. Date of completion of capital change registration: May 25, 115
3. Impact on financial statements (including differences in paid-in capital, shares outstanding, and book value per share):
Before Reduction: Paid-in Capital 3,799,093,700 NTD, Outstanding Shares 371,637,704, Book Value per Share 92.71 NTD
After Reduction: Paid-in Capital 3,799,013,700 NTD, Outstanding Shares 371,629,704, Book Value per Share 92.71 NTD
Note: Book value per share is calculated based on the financial statements reviewed by accountants for Q1 of 115.
4. Planned share exchange schedule: N/A
5. Expected listed common shares after reduction: N/A
6. Ratio of expected listed common shares to total issued common shares after reduction: N/A
7. Countermeasures for low liquidity: N/A
8. Other important items: The number of restricted employee shares canceled in this instance is 8,000 shares.
FAQ
Why did PharmaEssentia conduct this capital reduction?
To cancel restricted employee shares.
Does this affect the company's financials?
There is a slight decrease in paid-in capital, but no impact on book value per share.
When was it completed?
The registration was completed on May 25, 115.